Please note - this trial is no longer recruiting patients. We hope to add results when they are available. Polatuzumab vedotin is made up of the monoclonal antibody polatuzumab and the chemotherapy ...

A panelist discusses how various antibody-drug conjugates, including polatuzumab vedotin, pinatuzumab vedotin, and ...

Paolo Caimi, MD, spoke with Healio about the latest results from the POLARIX trial presented at ASH Annual Meeting and ...

The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes ...

The CHMP backed Polivy (polatuzumab vedotin) for previously-untreated diffuse large B-cell lymphoma (DLBCL) in combination with R-CHP chemotherapy (rituximab, cyclophosphamide, doxorubicin ...

Polivy (polatuzumab vedotin-piiq) has been granted accelerated approval in combination with bendamustine chemotherapy and Rituxan (rituximab) (BR) for adults with relapsed or refractory diffuse ...

Another study retrospectively evaluated the efficacy of polatuzumab vedotin using cell-of-origin (COO) subtyping via the Hans algorithm. COO classification was found to strongly predict activity ...

Roche has shared new long-term results from a phase 3 study of its anti-CD79b antibody-drug conjugate Polivy (polatuzumab vedotin) in patients with untreated diffuse large B-cell lymphoma (DLBCL), an ...